Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Psychiatric Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EAAT2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EAAT2 ECD Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed. |
View EAAT2 Products |
| Gene Delivery | EAAT2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for preserving native 8-TM conformation. |
View EAAT2 Products |
| Benchmark Ab | Anti-EAAT2 Recombinant Antibody Recombinant positive control for expression and localization assays. |
View EAAT2 Products |
| Validator | EAAT2 siRNA Set For knockdown verification and specificity controls in primary astrocytes. |
View EAAT2 Products |
| Related Target A | EAAT1 (SLC1A3) Subfamily member. Essential for off-target selectivity screening to avoid cerebellar toxicity. |
View EAAT1 Products |
| Related Target B | EAAT3 (SLC1A1) Subfamily member. Critical counter-screening target to ensure drug safety and specificity. |
View EAAT3 Products |
| Related Target C | GRM5 (mGluR5) Metabotropic glutamate receptor. Synergistic target in glutamate excitotoxicity pathways. |
View GRM5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 8-TM Protein | Lentivirus-mediated stable cell line construction preserves native multi-pass transmembrane structure. |
| Subfamily Selectivity (EAAT1 vs EAAT2 vs EAAT3) | Matched ortholog and homolog panels available, strictly sequence-verified. |
| Lack of Reliable Controls | Sequence-derived recombinant reference antibodies and validated siRNAs included in the catalog. |
| Assay Reproducibility | High-purity, endotoxin-controlled reagents ensuring minimal batch-to-batch variation. |
Live EAAT2/SLC1A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EAAT2 therapeutics is intensifying, with major players shifting focus from non-specific glutamate modulators to highly selective small molecule positive allosteric modulators (PAMs) and targeted gene therapies. As first-generation therapies for amyotrophic lateral sclerosis (ALS) and epilepsy reach advanced clinical phases, the next wave of R&D is targeting cell-type specific upregulation of EAAT2 to prevent localized excitotoxicity without causing systemic neurological side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PAMs | Biohaven, Academic Spin-offs | ALS, Alzheimer's Disease, Epilepsy | Glutamate uptake assays requiring stable cell lines (Lentivirus-driven EAAT2 expression). |
| Gene Therapy (AAV) | Audentes Therapeutics, Novartis | Amyotrophic Lateral Sclerosis (ALS) | In vitro expression validation using sequence-verified qPCR and western blot controls. |
| Monoclonal Antibodies | Research Institutions | Glioblastoma, Neuroimaging | Surface binding and flow cytometry validation (Need native conformation preservation). |